Modulating and Imaging Macrophage Reprogramming for Cancer Immunotherapy.

IF 3.7 Q2 GENETICS & HEREDITY
Phenomics (Cham, Switzerland) Pub Date : 2024-06-22 eCollection Date: 2024-08-01 DOI:10.1007/s43657-023-00154-6
Jialu Wang, Yafang Lu, Ren Zhang, Zhenzhen Cai, Zhan Fan, Yilun Xu, Zheng Liu, Zhihong Zhang
{"title":"Modulating and Imaging Macrophage Reprogramming for Cancer Immunotherapy.","authors":"Jialu Wang, Yafang Lu, Ren Zhang, Zhenzhen Cai, Zhan Fan, Yilun Xu, Zheng Liu, Zhihong Zhang","doi":"10.1007/s43657-023-00154-6","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer immunotherapy has made great progress in effectively attacking or eliminating cancer. However, the challenges posed by the low reactivity of some solid tumors still remain. Macrophages, as a key component of the tumor microenvironment (TME), play an important role in determining the progression of solid tumors due to their plasticity and heterogeneity. Targeting and reprogramming macrophages in TME to desired phenotypes offers an innovative and promising approach for cancer immunotherapy. Meanwhile, the rapid development of in vivo molecular imaging techniques provides us with powerful tools to study macrophages. In this review, we summarize the current progress in macrophage reprogramming from conceptual roadmaps to therapeutic approaches, including monoclonal antibody drugs, small molecule drugs, gene therapy, and chimeric antigen receptor-engineered macrophages (CAR-M). More importantly, we highlight the significance of molecular imaging in observing and understanding the process of macrophage reprogramming during cancer immunotherapy. Finally, we introduce the therapeutic applications of imaging and reprogramming macrophages in three solid tumors. In the future, the integration of molecular imaging into the development of novel macrophage reprogramming strategies holds great promise for precise clinical cancer immunotherapy.</p>","PeriodicalId":74435,"journal":{"name":"Phenomics (Cham, Switzerland)","volume":"4 4","pages":"401-414"},"PeriodicalIF":3.7000,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11584841/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phenomics (Cham, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s43657-023-00154-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Cancer immunotherapy has made great progress in effectively attacking or eliminating cancer. However, the challenges posed by the low reactivity of some solid tumors still remain. Macrophages, as a key component of the tumor microenvironment (TME), play an important role in determining the progression of solid tumors due to their plasticity and heterogeneity. Targeting and reprogramming macrophages in TME to desired phenotypes offers an innovative and promising approach for cancer immunotherapy. Meanwhile, the rapid development of in vivo molecular imaging techniques provides us with powerful tools to study macrophages. In this review, we summarize the current progress in macrophage reprogramming from conceptual roadmaps to therapeutic approaches, including monoclonal antibody drugs, small molecule drugs, gene therapy, and chimeric antigen receptor-engineered macrophages (CAR-M). More importantly, we highlight the significance of molecular imaging in observing and understanding the process of macrophage reprogramming during cancer immunotherapy. Finally, we introduce the therapeutic applications of imaging and reprogramming macrophages in three solid tumors. In the future, the integration of molecular imaging into the development of novel macrophage reprogramming strategies holds great promise for precise clinical cancer immunotherapy.

调节和成像巨噬细胞重编程,促进癌症免疫疗法。
癌症免疫疗法在有效攻击或消除癌症方面取得了巨大进展。然而,一些实体瘤的低反应性所带来的挑战依然存在。巨噬细胞作为肿瘤微环境(TME)的重要组成部分,由于其可塑性和异质性,在决定实体瘤的进展方面发挥着重要作用。将肿瘤微环境中的巨噬细胞靶向并重新编程为所需的表型,为癌症免疫疗法提供了一种创新且前景广阔的方法。同时,体内分子成像技术的快速发展为我们提供了研究巨噬细胞的有力工具。在这篇综述中,我们总结了目前巨噬细胞重编程从概念路线图到治疗方法的进展,包括单克隆抗体药物、小分子药物、基因治疗和嵌合抗原受体工程化巨噬细胞(CAR-M)。更重要的是,我们强调了分子成像在观察和理解癌症免疫治疗过程中巨噬细胞重编程过程中的重要意义。最后,我们介绍了巨噬细胞成像和重编程在三种实体瘤中的治疗应用。未来,将分子成像技术融入到新型巨噬细胞重编程策略的开发中,将为精确的临床癌症免疫疗法带来巨大希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信